NAD+ is a coenzyme present in all living cells that shuttles electrons in the redox reactions central to glycolysis, the TCA cycle, and oxidative phosphorylation. It is also a consumed co-substrate fo...
NAD+ is a coenzyme present in all living cells that shuttles electrons in the redox reactions central to glycolysis, the TCA cycle, and oxidative phosphorylation. It is also a consumed co-substrate for PARP enzymes during DNA base-excision repair and for sirtuins during protein deacetylation, linking cellular NAD+ availability to genome-stability maintenance and metabolic regulation. Cellular NAD+ levels decline with age. A systematic review of 8 randomized trials of the precursor NMN (342 participants) found no significant benefit on glucose, insulin, or lipid markers, and a separate review of 25 published human trials of the precursor NR concluded supplementation has shown few clinically relevant effects — an important gap between preclinical claims and confirmed human outcomes.
Current Diabetes Reports · 2024
Across 8 randomized trials (342 participants), the NAD+ precursor NMN showed no significant effect on glucose or lipid metabolic markers in mainly healthy adults.
View Source →Science Advances · 2023
Review of 25 human trials of the NAD+ precursor nicotinamide riboside concludes it has shown few clinically relevant effects in humans to date, despite favorable preclinical data.
View Source →Science · 2015
Foundational review establishing NAD+'s roles as a redox coenzyme and cosubstrate for sirtuins and PARPs, and its age-related decline as a therapeutic target.
View Source →-01M0DWXCV3E8SEZ4TAM87W0CNB.png)